Streetbeat News

Stock Prices

NBIX

Stifel analyst Paul Matteis has maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) and increased the price target from $141 to $144.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:38 pm

AAPL

Apple Inc. has seen its market cap grow by $1 trillion in 2023, surpassing $3 trillion. Analysts predict a potential rise to $4 trillion by end of 2024. Apple's stock hit record highs, recovering from a 15% drop to an 18% gain, and is now approaching the $200 level. The stock closed at $198.11 on December 14.

Portfolio Pulse from Zaheer Anwari

December 18, 2023 | 3:32 pm

FICO

Over the past 10 years, Fair Isaac (NYSE:FICO) has produced an average annual return of 33.58%, outperforming the market by 23.65% on an annualized basis. A $1000 investment in FICO a decade ago would be worth $18,146.05 today. Fair Isaac currently has a market capitalization of $27.92 billion.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 3:30 pm

MCHP

Microchip Technology (NASDAQ:MCHP) has delivered an average annual return of 16.56% over the past 15 years, outperforming the market. An investment of $1000 in MCHP 15 years ago would be worth $9,632.05 today. The company's current market capitalization stands at $49.97 billion. The key takeaway is the significant impact of compounded returns on investment growth over time.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 3:30 pm

CARA

Needham analyst Joseph Stringer has maintained a Buy rating on Cara Therapeutics (NASDAQ:CARA) but has reduced the price target from $22 to $6.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:29 pm

SPWR

SunPower shares are trading lower due to the company expressing substantial doubt about its ability to continue as a going concern, indicating potential financial distress.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:28 pm

GSK

GSK plc's Jemperli (dostarlimab) in combination with chemotherapy and Zejula (niraparib) met its primary endpoint in a phase 3 trial for advanced or recurrent endometrial cancer. The trial showed a significant benefit in progression-free survival, especially in patients with MMRp/MSS tumors. The safety profile was consistent with the individual drugs' known profiles. Endometrial cancer cases are rising, and MMRp/MSS cancer has limited treatment options. GSK's stock rose 1.18% on this news.

Portfolio Pulse from Vandana Singh

December 18, 2023 | 3:28 pm

SPWR

SunPower Corp (NASDAQ:SPWR) shares plummeted after the company expressed substantial doubt about its ability to continue as a going concern, citing breaches of credit agreement terms and delays in filing quarterly financial results. The company warned that its stock might become worthless if it fails to amend breaches under its Credit Agreement and Atlas Credit Agreement and cannot raise additional capital. SunPower's audit committee previously stated that financial reports for FY 2022 and the first two quarters should not be relied upon. Goldman Sachs analyst Brian Lee downgraded SunPower from Neutral to Sell and lowered the price target from $5 to $4.

Portfolio Pulse from Adam Eckert

December 18, 2023 | 3:25 pm

PBLA

Panbela Therapeutics Inc (NASDAQ:PBLA) stock rose by 9.7% to $0.50 after announcing FDA approval of eflornithine, a drug they divested to US WorldMeds, for high-risk neuroblastoma patients. Panbela may receive up to $9.5 million based on milestones from USWM. The approval is the first for a polyamine targeted therapy in cancer, with potential implications for other cancers. PBLA's 52-week range is $0.45 to $225.71.

Portfolio Pulse from Henry Khederian

December 18, 2023 | 3:18 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo provides daily trading strategies for SPY, QQQ, AAPL, MSFT, META, NVDA, TSLA, and GOOGL, based on a proprietary formula considering price, volume, and options flow. The memo outlines potential bullish and bearish price levels for these assets and advises traders to monitor the stocks closely for breakouts or reversals. The session's volatility may be influenced by the NAHB Housing Market Index and Treasury Bill Auction. The memo is part of a service offered by Market Clubhouse, which includes a live daily market analysis and real-time trading mentorship by a professional trader known as RIPS.

Portfolio Pulse from RIPS

December 18, 2023 | 3:16 pm